Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy Eva Wollmann,

Slides:

Advertisements

Similar presentations

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Advertisements

Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study Anna.

Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy Christian Lupinek, Kurt Derfler, Silvia Lee, Thomas Prikoszovich, Oliver Movadat,

Volume 11, Pages (September 2016)

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies Marija Geroldinger-Simic, MD, Thomas Zelniker,

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

Anthroposophic lifestyle is associated with a lower incidence of food allergen sensitization in early childhood Sara Fagerstedt, MSc, Helena Marell Hesla,

High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE Elizabeth A. Erwin,

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD

Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE Eva-Maria Varga, MD, Fahima Kausar, MSc, Werner.

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults Peter S. Creticos, MD, Jennifer Maloney,

Erika Lerch, MD, Ulrich R. Müller, MD

Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32 Verena Niederberger, MD, Angela Neubauer, PhD,

Julie Wang, MD, James H. Godbold, PhD, Hugh A. Sampson, MD

Persistence of the IgE repertoire in birch pollen allergy

Specific IgE and IgG measured by the MeDALL allergen-chip depend on allergen and route of exposure: The EGEA study Valérie Siroux, PhD, Christian Lupinek,

Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies

Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study Anna.

The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms Natasha C. Gunawardana,

Antibody conjugates bispecific for intercellular adhesion molecule 1 and allergen prevent migration of allergens through respiratory epithelial cell layers

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy.

Recombinant allergens: What does the future hold?

Allergen sensitization in a birth cohort at midchildhood: Focus on food component IgE and IgG4 responses Jeffrey M. Wilson, MD, PhD, Lisa Workman, BA,

In vivo allergenic activity of a hypoallergenic mutant of the major fish allergen Cyp c 1 evaluated by means of skin testing Nikolaos Douladiris, MD,

Analysis of serum IgE reactivity profiles with microarrayed allergens indicates absence of de novo IgE sensitizations in adults Christian Lupinek, MD,

Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel.

Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season Alexander Kettner, PhD, Gilles DellaCorte, MD,

Prediction of peanut allergy in adolescence by early childhood storage protein-specific IgE signatures: The BAMSE population-based birth cohort Anna.

Allergen microarray detects high prevalence of asymptomatic IgE sensitizations to tropical pollen-derived carbohydrates Clarissa R. Cabauatan, PhD, Christian.

Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms Raffaela.

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

Phillip Lieberman, MD, Michael Tankersley, MD

Journal of Allergy and Clinical Immunology

Early decreases in blood eosinophil levels with reslizumab

Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens Brian P. Vickery, MD, Jing Lin, PhD, Michael Kulis, PhD, Zhiyan Fu,

The Editors’ Choice Journal of Allergy and Clinical Immunology

Epicutaneous immunotherapy for peanut allergy modifies IgG4 responses to major peanut allergens Stef J. Koppelman, PhD, Aurélie Peillon, MSc, Wenceslas.

Determination of IgE and IgG reactivity to more than 170 allergen molecules in paper- dried blood spots Victoria Garib, MD, PhD, Eva Rigler, MD, PhD,

Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis Natalija Novak, MD,

Underestimation of house dust mite–specific IgE with extract-based ImmunoCAPs compared with molecular ImmunoCAPs Huey-Jy Huang, MSc, Yvonne Resch-Marat,

Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma Oliver.

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

Selection of house dust mite–allergic patients by molecular diagnosis may enhance success of specific immunotherapy Kuan-Wei Chen, PhD, Petra Zieglmayer,

Evaluation of Allergen Immunotherapy

Different IgE recognition of mite allergen components in asthmatic and nonasthmatic children Yvonne Resch, MSc, Sven Michel, MSc, Michael Kabesch, MD,

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis Thomas B. Casale, MD, William.

Nasal AMP and histamine challenge within and outside the pollen season in patients with seasonal allergic rhinitis Sriram Vaidyanathan, MBBS, Peter Williamson,

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? Marianne Witten, MD, PhD, Hans-Jørgen Malling, MD, Lars.

CD23 surface density on B cells is associated with IgE levels and determines IgE- facilitated allergen uptake, as well as activation of allergen-specific.

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years Ronald Dahl, MD,

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies Marija Geroldinger-Simic, MD, Thomas Zelniker,

Peach allergy in China: A dominant role for mugwort pollen lipid transfer protein as a primary sensitizer Zhong-Shan Gao, PhD, Zhao-Wei Yang, BSc, Shan-Dong.

Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly Raffaela Campana, PhD, Susanne Vrtala,

Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis:

Peanut oral immunotherapy decreases IgE to Ara h 2 and Ara h 6 but does not enhance sensitization to cross-reactive allergens Riikka Uotila, MD, Anna.

Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study Maurizio Marogna, MD, Igino Spadolini, MD, Alessandro.

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity James N. Francis, PhD, Louisa.

Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy Johannes Martin Schmid, MD, Peter Adler Würtzen, PhD,

Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy– treated mother Sabine Flicker, PhD, Katharina Marth, MD, Heinz.

Fiftieth Annual Meeting of the American Academy of Allergy and Immunology: Anaheim, California, March 1994 Lawrence M. Lichtenstein, MD, PhD Journal.

Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen Piyush Patel, MD, Tom Holdich, MBBS,

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Role of Art v 3 in pollinosis of patients allergic to Pru p 3

Monitoring the epitope recognition profiles of IgE, IgG1, and IgG4 during birch pollen immunotherapy Barbara Gepp, MSc, Nina Lengger, BMA, Christian.

Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence Marit Westman, MD, Christian Lupinek,

The Editors' Choice Journal of Allergy and Clinical Immunology

Presentation transcript:

Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy Eva Wollmann, MD, Christian Lupinek, MD, Michael Kundi, PhD, Regina Selb, MSc, Verena Niederberger, MD, Rudolf Valenta, MD Journal of Allergy and Clinical Immunology Volume 136, Issue 3, Pages 806-809.e7 (September 2015) DOI: 10.1016/j.jaci.2015.02.034 Copyright © 2015 The Authors Terms and Conditions

Fig 1 Courses of geometric means and 95% CIs of Bet v 1–specific IgE (A: ImmunoCAP; B: ISAC) and IgG (C: ImmunoCAP; D: ISAC) levels (y-axes) over the study period (x-axes) for placebo- (blue), fragment- (green), and trimer-treated patients (orange). *P < .05 and **P < .01. Asterisks show the significance of changes within particular groups from the time point before treatment to after treatment, from after treatment to after season, and from after season to after 1 year. ISU, ISAC Standardized Unit. Journal of Allergy and Clinical Immunology 2015 136, 806-809.e7DOI: (10.1016/j.jaci.2015.02.034) Copyright © 2015 The Authors Terms and Conditions

Fig 2 Association of alterations in Bet v 1–specific IgE levels determined by ISAC and nasal allergen tolerance. Y-axes (positive range) indicate increased allergen-specific tolerance, wherein 1-point increase indicates tolerance of a 10-fold higher allergen concentration and 1-point decrease indicates a 10-fold higher sensitivity. X-axes indicate the log fold changes of Bet v 1–specific IgE when comparing prestudy levels (ie, before treatment; see Fig 1 and Fig E1) to levels after the pollen season (ie, after season; see Fig 1 and Fig E1). ISU, ISAC Standardized Unit. Journal of Allergy and Clinical Immunology 2015 136, 806-809.e7DOI: (10.1016/j.jaci.2015.02.034) Copyright © 2015 The Authors Terms and Conditions

Fig E1 Timeline of the SIT study. Blue arrows indicate the time points when blood samples were taken (before treatment, after treatment, after season, after 1 year). Nasal provocation tests analyzed in this study were performed before treatment (November/December 2000) and after season (May 2001). Journal of Allergy and Clinical Immunology 2015 136, 806-809.e7DOI: (10.1016/j.jaci.2015.02.034) Copyright © 2015 The Authors Terms and Conditions

Fig E2 Courses of geometric means and 95% CIs of Aln g 1 (A and B) and Cor a 1 (C and D)-specific IgE and IgG levels. *P < .05 and **P < .01. Asterisks show the significance of changes within particular groups from the time point before treatment to after treatment, from after treatment to after season, and from after season to after 1 year. Journal of Allergy and Clinical Immunology 2015 136, 806-809.e7DOI: (10.1016/j.jaci.2015.02.034) Copyright © 2015 The Authors Terms and Conditions

Fig E3 Course of geometric means and 95% CIs of Mal d 1 (A and B) or Pru p 1 (C and D)-specific IgE and IgG levels. *P < .05 and **P < .01. Asterisks show the significance of changes within particular groups from the time point before treatment to after treatment, from after treatment to after season, and from after season to after 1 year. Journal of Allergy and Clinical Immunology 2015 136, 806-809.e7DOI: (10.1016/j.jaci.2015.02.034) Copyright © 2015 The Authors Terms and Conditions

Fig E4 Association of alterations in Bet v 1–specific IgE levels determined by ImmunoCAP and nasal allergen tolerance. Y-axes (positive range) indicate increased allergen-specific tolerance, wherein 1-point increase indicates tolerance of a 10-fold higher allergen concentration and 1-point decrease indicates a 10-fold higher sensitivity. X-axes indicate the log fold changes of Bet v 1–specific IgE when comparing prestudy levels (ie, before treatment; see Fig 1 and Fig E1) to levels measured after the pollen season (ie, after season; see Fig 1 and Fig E1). Journal of Allergy and Clinical Immunology 2015 136, 806-809.e7DOI: (10.1016/j.jaci.2015.02.034) Copyright © 2015 The Authors Terms and Conditions